Company intelligence / Profile preview

NanoSomiX

Aliso Viejo, California, United States

Ownership: Private
Employees: ~6
Development stage: Other

Overview

NanoSomiX has developed blood-based assays to measure biomarkers from brain-derived exosomes for non-invasive brain analysis. The company has demonstrated the ability to detect Alzheimer's disease risk up to 10 years before clinical diagnosis and is currently focused on clinical target discovery and validation through various collaborations.

Therapeutic areas: Neurology
Modalities: Exosome-based diagnostics
Industry: Protein Biomarker Diagnostics

Partnerships

Academic research institutionsPharmaceutical companies (unspecified)Fight Club OC (concussion research)

Beyond the preview

Go deeper on NanoSomiX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoSomiX.

Explore the full profile